The FDA has granted fast track designation to MT-125 for the treatment of patients with glioblastoma. The U.S. Food and Drug ...

MT-125, a dual small-molecule inhibitor, received FDA fast track designation for glioblastoma, facilitating expedited drug ...

Short-course HSRT regimens yielded higher response and PFS rates at 6 months in patients with recurrent high-grade glioma.

Longitudinal GBM biopsies uncovered effects of immunotherapy that could not be surmised by routine MRI or clinical analyses.

Cintredekin besudotox targets IL-13 alpha-2 receptor in glioblastoma, aiming to spare healthy brain tissue while destroying cancer cells. Orphan drug designation offers benefits like lower fees and ...

The tool, called PICTURE (Pathology Image Characterization Tool with Uncertainty-aware Rapid Evaluations), distinguished with near-perfect accuracy between glioblastoma—the most common and aggressive ...

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The ...

BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: ...

The Agency is now requiring the submission of confirmatory efficacy data to support the application. The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Outlook ...

A chemotherapy-free regimen combining nogapendekin alfa, NK cell therapy, and TTFields showed a 100% disease control rate in recurrent GBM patients. The pilot study reported three objective responses, ...

Curasight A/S has received clinical trial approval from the EMA for phase I evaluation of Utreat as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. The trial will enroll ...